Table 3.
Multivariable Cox regression for analyzing the CSS among primary NSCLC patients with BM (diagnosed 2010–2014)
| Variables | Number of patients with BM (2010–2014) | Median survival time (95% CI, month) | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Overall (CSS) | Deceased (%, CSS) | ||||
| Age | 1.166 (1.137–1.197) | < 0.001 | |||
| < 50 | 351 | 303 (86.32%) | 7 (5.913–8.087) | 1.00 | – |
| 50–59 | 1190 | 1084 (91.09%) | 5 (4.500–5.500) | 1.265 (1.113–1.437) | < 0.001 |
| 60–69 | 1844 | 1666 (90.35%) | 5 (4.574–5.426) | 1.342 (1.187–1.518) | < 0.001 |
| 70–79 | 1600 | 1505 (94.06%) | 4 (3.718–4.282) | 1.676 (1.479–1.899) | < 0.001 |
| ≥80 | 679 | 643 (94.70%) | 3 (2.687–3.313) | 1.930 (1.679–2.218) | < 0.001 |
| Race | 0.864 (0.827–0.902) | < 0.001 | |||
| White | 4388 | 4081 (93.00%) | 4 (3.802–4.198) | 1.00 | – |
| Black | 739 | 686 (92.83%) | 4 (3.550–4.450) | 1.028 (0.947–1.117) | 0.507 |
| Other | 537 | 434 (80.82%) | 10 (8.408–11.592) | 0.675 (0.610–0.747) | < 0.001 |
| Marital status | |||||
| Unmarried | 2491 | 2326 (93.38%) | 3 (2.765–3.235) | 1.00 | – |
| Married | 3173 | 2875 (90.61%) | 5 (4.692–5.308) | 0.817 (0.772–0.865) | < 0.001 |
| Sex | |||||
| Male | 3303 | 3085 (93.40%) | 4 (3.767–4.233) | 1.00 | – |
| Female | 2361 | 2116 (89.62%) | 5 (4.629–5.371) | 0.805 (0.760–0.852) | < 0.001 |
| Tumor histology | 1.305 (1.242–1.370) | < 0.001 | |||
| Adenocarcinoma | 3962 | 3555 (89.73%) | 5 (4.703–5.297) | 1.00 | – |
| Squamous cell carcinoma | 1414 | 1365 (96.53%) | 3 (2.704–3.296) | 1.363 (1.276–1.456) | < 0.001 |
| Other | 288 | 281 (97.57%) | 2 (1.616–2.384) | 1.534 (1.346–1.747) | < 0.001 |
| Laterality | 1.035 (0.983–1.090) | 0 0.189 | |||
| Left | 2262 | 2077 (91.82%) | 5 (4.645–5.355) | 1.00 | – |
| Right | 3292 | 3021 (91.77%) | 4 (3.772–4.228) | 1.038 (0.982–1.099) | 0.189 |
| Paired | 110 | 103 (93.64%) | 4 (2.473–5.527) | 1.053 (0.861–1.287) | 0.614 |
| T stage | 1.077 (1.046–1.109) | < 0.001 | |||
| T1 | 472 | 415 (87.92%) | 7 (6.010–7.990) | 1.00 | – |
| T2 | 1549 | 1415 (91.35%) | 5 (4.557–5.443) | 1.203 (1.077–1.344) | 0.001 |
| T3 | 1568 | 1441 (91.90%) | 4 (3.679–4.321) | 1.244 (1.113–1.392) | < 0.001 |
| T4 | 2075 | 1930 (93.01%) | 4 (3.728–4.272) | 1.319 (1.181–1.473) | < 0.001 |
| N stage | 1.077 (1.046–1.109) | < 0.001 | |||
| N0 | 1098 | 982 (89.44%) | 5 (4.449–5.551) | 1.00 | – |
| N1 | 492 | 440 (89.43%) | 5 (4.251–5.749) | 1.007 (0.899–1.127) | 0.904 |
| N2 | 2884 | 2675 (92.75%) | 4 (3.754–4.246) | 1.162 (1.079–1.252) | < 0.001 |
| N3 | 1190 | 1104 (92.77%) | 4 (3.514–4.486) | 1.153 (1.055–1.259) | 0.002 |
| Grade | 1.141 (1.090–1.195) | < 0.001 | |||
| 1 | 264 | 238 (90.15%) | 6 (4.535–7.465) | 1.00 | – |
| 2 | 1733 | 1549 (89.38%) | 6 (5.456–6.544) | 1.049 (0.914–1.203) | 0.497 |
| 3 | 3529 | 3280 (92.94%) | 4 (3.804–4.196) | 1.234 (1.081–1.410) | 0.002 |
| 4 | 138 | 134 (97.10%) | 3 (2.330–3.670) | 1.387 (1.112–1.731) | 0.004 |
| Brain metastases | |||||
| No | 4331 | 3966 (91.57%) | 4 (3.756–4.244) | 1.00 | – |
| Yes | 1333 | 1235 (92.65%) | 4 (3.698–4.302) | 1.214 (1.136–1.297) | < 0.001 |
| Liver metastases | |||||
| No | 4393 | 3978 (90.55%) | 5 (4.731–5.269) | 1.00 | – |
| Yes | 1271 | 1223 (96.22%) | 3 (2.715–3.285) | 1.392 (1.303–1.487) | < 0.001 |
| Lung metastases | |||||
| No | 3892 | 3562 (91.52%) | 5 (4.760–5.240) | 1.00 | – |
| Yes | 1772 | 1639 (92.49%) | 4 (3.648–4.352) | 1.029 (0.965–1.098) | 0.376 |